Cognition Therapeutics schedules Type C FDA meeting on zervimesine Phase 3 DLB endpoints
Cognition Therapeutics scheduled a Type C meeting with the FDA for October 20, 2026 to align on endpoints for its Phase 3 trial of zervimesine (CT1812) in DLB.
Story updates
11:32:40 AM UTC
SquawkNews
Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB
Sept. 29 — Cognition Therapeutics Inc said it has scheduled a Type C meeting with the FDA to align on endpoints for its Phase 3 trial of zervimesine (CT1812) in DLB. The company said the meeting is set for October 20, 2026, and will focus on the primary endpoint for the Phase 3 DLB study.